Table 2.
Comparison between malignant and non-malignant clinical and paraclinical features.
| VARIABLE | MALIGNANT n = 6 | NON-MALIGNANT n = 12 | p-vALUE |
|---|---|---|---|
| AGE, YEAR | 72 (63–75) | 64 (41–73) | 0.015 |
| BODY MASS INDEX (KG/M2) | 25.4 (16.5–32.4) | 24.2 (17.0–41.6) | >0.999 |
| SEX RATIO/MALE: FEMALE | 2:4 | 6:6 | 0.502 |
| ASA SCORE | 2 [2,3] | 2 [2,3] | 0.668 |
| ASAT (UI/L) | 20 (17–95) | 23 (12–55) | 0.807 |
| ALAT (UI/L) | 19 (14–196) | 22 (10–108) | 0.903 |
| CA19-9 (U/ML) | 137 (17–783) | 5 (2–57) | 0.030 |
| AMYLASE (UI/L) | 24 (22–183) | 31 (29–59) | 0.5676 |
| LIPASE (UI/L) | 148 (28–267) | 42 (26–112) | 0.889 |
| GGT (UI/L) | 27 (20–1399) | 23 (6–148) | 0.3162 |
| ALKALINE PHOSPHATASE (UI/L) | 270 (73–467) | 70 (48–108) | 0.191 |
| TOTAL BILIRUBIN (μMOL/L) | 10 (7–258) | 10 [[6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35]] | >0.999 |
| DIRECT BILIRUBIN (μMOL/L) | 10 (3–255) | 10 [[3], [4], [5], [6], [7], [8], [9], [10]] | 0.622 |
| TUMOR SIZE (IRM/CT) (IN MM) | 42.0 (24.0–60.0) | 29.5 (12.0–45.0) | 0.134 |
| TYPE OF IPMN, MAIN/BRANCH/MIXED | 2/0/4 | 2/4/6 | 0.259 |
| PRE-PATHOLOGICAL EXAMINATION | 3 (50.0%) | 2 (16.7%) | 0.137 |